Saby George, MD
Medical Oncology · Buffalo, NYNPI 1063686418
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $175,916 of the $234,276 with a category attached, or 75.1%. 18 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 27.1% of the total. Reporting peaked in 2023 at $44,997 and has fallen 51.5% since, to $21,838 in 2025. Among medical oncology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 198 payments — averaging $1183.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$63K
- Merck$34K
- EMD Serono, Inc.$29K
- Eisai Inc.$21K
- Bayer$20K
- Exelixis Inc.$19K
- plus $47K from 12 others
Across 542 payments — averaging $27,413 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$8M
- Merck$4.1M
- E.r. Squibb & Sons, L.L.C.$1.4M
- Seagen Inc.$451K
- Exelixis Inc.$276K
- Pfizer$197K
- plus $472K from 7 others
What the payments were for
- Consulting fees$175,91675%
- Speaking & faculty fees$24,44010%
- Travel & lodging$18,9618%
- Food & beverage$7,2233%
- Education$7,7173%
- Entertainment$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 29 | $63,492 |
| Merck | 15 | $33,647 |
| EMD Serono, Inc. | 16 | $29,283 |
| Eisai Inc. | 17 | $20,769 |
| Bayer | 20 | $20,184 |
| Exelixis Inc. | 48 | $19,493 |
| Sanofi | 4 | $12,345 |
| AstraZeneca | 9 | $6,620 |
| Novartis | 5 | $6,066 |
| Pfizer | 14 | $4,956 |
| Seagen Inc. | 5 | $4,407 |
| AVEO Pharmaceuticals, Inc. | 10 | $4,213 |
| Immunomedics, Inc. | 1 | $2,700 |
| GSK | 1 | $2,175 |
| Janssen Global Services, LLC | 1 | $2,025 |
| Johnson & Johnson | 1 | $1,763 |
| Janssen Scientific Affairs, LLC | 1 | $77 |
| Astellas Pharma US Inc | 1 | $61 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$234,276 in reported general payments places this provider in the 90th percentile of 498 medical oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Buffalo
- Ehsan MalekBuffalo$826K
- Marco DavilaBuffalo$437K
- Nikhil KhushalaniBuffalo$193K
- Francisco Hernandez IlizaliturriBuffalo$158K
- Craig ThompsonNew York$4.8M
- Andrew SeidmanNew York$1.3M
- Maria TheodoulouAlbany$1.1M
- Joshua RichterNew York$971K
- Edward GelmannNew York$944K
- Anthony MatoIthaca$909K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.